Glucagon Market Size & Share 2026-2035

Glucagon Market Size

The global glucagon market was valued at USD 466.5 million in 2025 and is projected to grow from USD 491.5 million in 2026 to USD 866.8 million by 2035, expanding at a CAGR of 6.5%, according to the latest report published by Global Market Insights Inc.

The global market is mainly driven by the increasing prevalence of diabetes and growing incidence of hypoglycemia, which have been imposing a huge burden on the global population. According to the International Diabetes Federation (IDF) Diabetes Atlas 2025, an estimated 589 million adults (20-79 years) were living with diabetes in 2024, and this number is expected to rise to 853 million by 2050.  The rise in the diabetic population is proportionally increasing the risk of hypoglycemia especially among insulin-dependent patients, thereby driving the demand for rapid-acting rescue drugs such as glucagon.
 

The market has grown from USD 402.3 million in 2022 to USD 443.6 million in 2024. Besides the growing burden of diabetes-related hypoglycemia, technological advancements in glucagon delivery systems are playing a significant role in driving the growth of the glucagon market. Over the past few years, the diabetes care landscape has shifted toward more integrated, automated, and user‑friendly solutions, supported by rapidly advancing digital health ecosystems. The top 5 players in the market include Amphastar, Xeris Biopharma, Novo Nordisk, Fresenius Kabi, and Lupin.
 

Further highlighting this trend, a systematic review published in Springer Nature, in 2025 showed that diabetes‑related hypoglycemia is rising globally, with significant direct and indirect costs associated with hospitalization, emergency care, productivity losses, and caregiver burden. The review reported that annual hypoglycemia‑attributable costs ranged from USD 1,431 to USD 14,414 per patient per year, underscoring the growing severity and frequency of such events. This escalating economic and clinical impact has reinforced the urgent need for effective emergency treatments, positioning glucagon as a critical therapy in diabetes management.

The market refers to the commercial landscape surrounding glucagon, a critical hormone used to rapidly raise blood glucose levels during episodes of severe hypoglycemia, particularly in individuals with diabetes who use insulin.

Glucagon Market Trends

• Technological innovation in glucagon formulations has transformed the management of severe hypoglycemia, shifting the market away from traditional multi‑step reconstitution kits toward ready‑to‑use, highly stable, and patient‑friendly options. These advancements span across formulation science, drug‑device integration, and new delivery technologies aimed at improving reliability, usability, and clinical outcomes in emergency situations.
   
• A breakthrough innovation is the development of stable liquid glucagon formulations that remain usable at room temperature without requiring mixing. These ready‑to‑use injectables delivered via autoinjectors, or prefilled syringes significantly reduce administration time and complexity. By removing the multi‑step preparation process associated with older lyophilized kits, these innovations enhance ease of use for caregivers, school personnel, and emergency responders, increasing the likelihood of timely treatment during acute hypoglycemia episodes.
   
• Additionally, advancements in pharmaceutical processing and manufacturing technologies have enabled improved formulation stability, scalability, and product consistency. Automation, precision‑controlled bioprocessing, and enhanced quality‑assurance systems support high‑volume, cost‑efficient production, facilitating wider availability of glucagon across global markets.
   
• Looking ahead, research into personalized glucagon dosing and precision delivery may enable tailored therapies for individuals with varying metabolic responses. Parallel work in microneedle patches, miniaturized delivery systems, and pump‑based glucagon platforms suggests future expansion of glucagon use beyond emergency rescue, potentially supporting continuous or episodic glucose regulation in specialized clinical scenarios.
   

Glucagon Market Analysis

Based on product type, the market is divided into injectable and inhalation. The injectable segment dominated the market accounting for 52.4% of revenue share in 2025.
 

• Injectable formulations deliver a swift onset of action typically within minutes making them indispensable during severe hypoglycemia events where rapid glucose elevation is critical to preventing seizures, loss of consciousness, or long‑term neurological injury.
   
• The clinical value of injectable glucagon is reinforced by its versatility in administration routes, including subcutaneous, intramuscular, and intravenous delivery. This flexibility enables use across multiple care environments from at‑home emergencies handled by caregivers to hospital settings where clinicians may require IV administration for faster systemic uptake. The ability to tailor administration based on patient condition and urgency contributes significantly to the segment’s sustained market leadership.
   
• Technological advancements in drug‑device integration continue to strengthen this segment. The emergence of prefilled syringes, auto‑injectors, and combination rescue kits reduces user error and enhances confidence during high‑stress emergencies. Enhanced stability profiles, improved formulation characteristics, and reduced preparation steps have allowed injectable glucagon to retain clinical relevance even as newer intranasal options enter the landscape.
   
• As a result, the injectable segment benefits from a well‑established clinical history, dosage flexibility, rapid onset, and broad user familiarity, all of which collectively support its dominant market share and continued preference among healthcare professionals and patients.
   

Based on application, the glucagon market is bifurcated into hypoglycemia, diagnostic aid, gastrointestinal disorders, cardiogenic shock, and other applications. The hypoglycemia segment accounted for a 34.3% market share in 2025 and is projected for significant growth to reach USD 296.9 million by 2035.
 

• This segment’s dominance is attributed to glucagon’s critical clinical role as a firstline rescue therapy for severe, symptomatic, or unconscious hypoglycemia in individuals with diabetes.
   
• Glucagon’s rapid mechanism of action is central to the segment’s growth. When administered, glucagon promptly stimulates hepatic glycogen breakdown, causing glucose levels to rise quickly an essential response when hypoglycemia leads to confusion, dizziness, sweating, seizures, or loss of consciousness. The drug is explicitly indicated for the treatment of severe hypoglycemia in adults and children, and its fast action has been demonstrated across injectable and intranasal forms.
   
• Market expansion is also driven by rising global diabetes incidence, which enlarges the population using insulin and sulfonylureas, two therapies associated with elevated hypoglycemia risk. With more individuals vulnerable to severe events, the need for reliable emergency glucagon intervention continues to grow worldwide.
   
• Overall, the hypoglycemia segment’s dominance is supported by glucagon’s life‑saving speed of action, its necessity in non‑oral rescue scenarios, broadening institutional access, and expanding diabetes burden all of which collectively sustain the segment’s strong trajectory toward 2035.
   

Based on distribution channel, the glucagon market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment accounted for a USD 222.1 million in 2025.
 

• Hospital pharmacies ensure continuous availability, correct handling, and safe administration of glucagon across emergency departments, inpatient wards, intensive care units, and diagnostic imaging suites.
   
• Hospital pharmacists possess specialized expertise in medication handling, storage, and administration, ensuring glucagon remains stable, properly stored, and ready for immediate use, that hospital pharmacies are specifically trained to maintain.
   
• Hospital settings also serve as critical training environments, where pharmacists educate nurses, residents, and support staff on proper glucagon administration techniques to ensure safe, timely, and effective care. Educational materials emphasize correct preparation, administration steps, and post‑treatment monitoring to prevent complications.
   
• Overall, the hospital pharmacies segment benefits from professional oversight, dosage‑customization capabilities, multidimensional clinical use and guaranteed product readiness.
   

North America Glucagon Market

• North America accounted for the largest share of the global market in 2025, supported by an advanced healthcare system, high utilization of emergency diabetes therapies, and strong clinical adoption of ready‑to‑use glucagon formulations.
   
• The region benefits from well‑established hospital networks, widespread pharmacy availability, and robust regulatory frameworks that enable rapid approval and distribution of innovative glucagon products.
   
• The growing diabetes burden is a primary driver of glucagon demand. In Canada alone, 3.9 million people (9.7% of the population aged 1 year and older) are living with diagnosed diabetes during 2023–2024, according to Government of Canada surveillance data.
   
• Strong pharmacy and hospital distribution networks further reinforce regional dominance. Hospital pharmacies maintain glucagon as a critical emergency medication, ensuring proper storage and immediate access for severe hypoglycemia treatment. They also prepare weight‑adjusted pediatric doses and supply diagnostic GI‑procedure glucagon. Retail and online pharmacies complement this by providing widespread access to prescription glucagon products for at‑home preparedness.
   
• With rising diabetes prevalence, increasing adoption of ready‑to‑use glucagon, and continued emphasis on hypoglycemia safety standards and emergency preparedness, North America is expected to maintain its leading position in the global market throughout the forecast period.
   

The U.S. glucagon market was valued at USD 152.1 million and USD 159.5 million in 2022 and 2023, respectively. The market size reached USD 175.3 million in 2025, growing from USD 167 million in 2024.

• The U.S. represents the largest market for glucagon globally, supported by a mature healthcare ecosystem, extensive emergency‑care infrastructure, and broad adoption of advanced glucagon delivery technologies. Hospitals, urgent‑care centers, EMS units, and retail pharmacies maintain consistent access to glucagon, ensuring preparedness for severe hypoglycemia events among at‑risk populations.
   
• The clinical burden of diabetes significantly drives glucagon utilization. According to the CDC’s 2026 National Diabetes Statistics Report, 2.1 million people in the U.S. are living with diagnosed Type 1 diabetes, including 1.8 million adults aged ≥20 years and 314,000 children and adolescents younger than 20.
   
• Type 1 diabetes is strongly associated with recurrent hypoglycemia, especially among insulin‑treated individuals, making glucagon a critical emergency therapy within this population.
   
• Growing emphasis on emergency preparedness in community settings further strengthens the U.S. glucagon market. Schools, workplaces, public institutions, and long‑term care facilities increasingly stock glucagon for rapid response to Level 3 hypoglycemia. This trend aligns with ADA recommendations emphasizing broader availability of glucagon for anyone at risk of severe events.
   
• With a high national prevalence of diabetes, substantial numbers of insulin‑dependent patients, expanding access policies, and continuous innovation from leading manufacturers, the U.S. is expected to maintain its position as the dominant market throughout the forecast period, driving adoption of both injectable and intranasal rescue therapies.
   

Europe Glucagon Market

Europe market accounted for USD 102 million in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• Europe holds a strong and influential position in the global market, supported by mature healthcare systems, established clinical guidelines for diabetes care, and broad access to emergency hypoglycemia treatments.
   
• The region has an extensive network of hospitals, outpatient clinics, and community pharmacies that ensure timely availability of glucagon particularly for insulin‑treated patients at high risk of severe hypoglycemia.
   
• A major driver of glucagon demand in Europe is the high and growing burden of diabetes. According to the International Diabetes Federation, the region is home to 65.6 million adults aged 20–79 years living with diabetes in 2024, a figure expected to rise to 72.4 million by 2050.
   
•  This continued growth in the insulin‑using population increases the likelihood of severe hypoglycemia events, strengthening the need for reliable and rapid glucagon rescue medications across emergency, outpatient, and home‑care settings
   
• With rising diabetes prevalence, expanding access to modern glucagon delivery systems, strong healthcare infrastructure, and increasing emphasis on preventing severe hypoglycemia‑related complications, Europe is expected to maintain a robust and growing presence in the global market throughout the forecast period.
   

The glucagon market in Germany is expected to experience significant and promising growth from 2025 to 2034.
 

• According to the International Diabetes Federation (IDF), an estimated 8-8.9 million people in the country were suffering from diabetes. The prevalence is projected to reach around 12 million by 2040, accumulating an estimated 500,000 newly diagnosed patients each year. These figures are part of the global burden of 537 million people with diabetes worldwide, illustrating Germany’s position within one of the largest and fastest‑growing diabetes populations globally.
   
• German clinicians follow stringent diabetes management guidelines, emphasizing hypoglycemia prevention and preparedness. This results in proactive prescribing of glucagon for at‑risk patients, especially those with Type 1 diabetes or those using intensive insulin regimens. Germany’s strong emphasis on patient education through diabetes centers, public health programs, and disease‑management groups also supports the widespread use of glucagon rescue medications.
   
• With continuous innovation in drug‑device combinations and a growing focus on emergency hypoglycemia management, Germany is expected to maintain a strong and expanding role in the European market. The increasing diabetes burden, coupled with robust healthcare investment and rapid adoption of next‑generation glucagon delivery systems, positions Germany as a key driver of regional market growth throughout the forecast period.
   

Asia Pacific Glucagon Market

The Asia Pacific region is projected to show a lucrative growth of about 7% during the forecast period.
 

• South‑East Asia is emerging as one of the fastest‑growing regions in the global market, driven by a rapidly expanding diabetic population, rising incidence of insulin‑treated patients, and growing awareness of severe hypoglycemia management.
   
• The region’s evolving healthcare infrastructure particularly in countries such as India, Indonesia supports increasing adoption of emergency glucagon therapies across hospitals, clinics, and community care settings.
   
• The diabetes burden in SEA is a major catalyst for glucagon demand. According to the International Diabetes Federation, the region is home to 106.9 million adults (20–79 years) living with diabetes in 2024, a number projected to surge to 184.5 million by 2050, representing one of the highest growth rates globally.
• This rapidly expanding diabetic population particularly the large number of insulins‑dependent Type 2 and Type 1 patients creates a significant need for fast‑acting glucagon rescue options to treat severe hypoglycemia.
   
• With a large and rapidly growing diabetes population, rising use of intensive insulin therapies, and substantial improvements in healthcare access and emergency preparedness, South‑East Asia is positioned to remain one of the fastest‑growing regions in the global market throughout the forecast period.
   

Japan glucagon market is anticipated to witness lucrative growth between 2026 – 2035.
 

• Japan is one of the most important markets in Asia‑Pacific, backed by a highly advanced healthcare infrastructure, strong national diabetes management programs, and robust regulatory oversight.
   
• Hospitals, emergency departments, and specialist diabetes centers in Japan maintain high standards of care, ensuring reliable availability and appropriate use of glucagon for severe hypoglycemia. This well‑structured system positions Japan as a regional leader in emergency diabetes treatment.
   
• A substantial and growing diabetes burden is a key driver of glucagon demand in Japan. According to the International Diabetes Federation, Japan had 8,970,500 adults living with diabetes in 2024, representing an 8.1% prevalence within the adult population in the country.
   
• As a large share of these individuals are insulin‑dependent, the clinical risk of severe hypoglycemia remains high reinforcing the need for dependable rescue therapies such as injectable and intranasal glucagon.
   
• Japan’s aging population intensifies the need for emergency hypoglycemia management. Older adults face higher rates of glycemic instability and impaired hypoglycemia awareness, making glucagon a critical component of emergency preparedness. Hospitals and long‑term care institutions routinely stock glucagon for rapid response when patients cannot consume oral glucose due to confusion or loss of consciousness.
   
• With a large and aging diabetic population, strong regulatory support, and continuous innovation in glucagon formulations and delivery devices, Japan is expected to remain a key growth market for glucagon in the Asia‑Pacific region throughout the forecast period.
   

Latin America Glucagon Market

Brazil is experiencing significant growth in the market.
 

• Brazil is one of the most important markets in Latin America, supported by its large diabetic population, expanding healthcare infrastructure, and growing emphasis on emergency management of severe hypoglycemia.
   
• The diabetes burden in Brazil is a major driver of glucagon utilization. In 2024, Brazil recorded 16,621,400 adults living with diabetes, representing a 10.6% prevalence within an adult population of 155,426,300.
   
• A substantial proportion of these individuals rely on insulin therapy placing them at heightened risk for severe hypoglycemia, where glucagon is essential for rapid reversal when patients become unconscious or unable to ingest oral glucose.
   
• Demographic shifts are amplifying demand for glucagon. Brazil’s population is aging quickly, and older adults have reduced counter‑regulatory responses and impaired hypoglycemia awareness. This increases their likelihood of severe episodes and strengthens the need for reliable rescue therapies. As Brazil’s elderly population expands, so does the long‑term market requirement for emergency glucagon solutions.
   
• With one of the largest diabetic populations in Latin America, rising use of intensive insulin regimens, an aging demographic, and ongoing improvements in healthcare delivery, Brazil is expected to remain a key growth market for glucagon throughout the forecast period.
   

Middle East and Africa Glucagon Market

The market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi Arabia is one of the most significant markets in the Middle East, driven by Vision 2030 healthcare reforms, expansion of modern hospitals, and increased prioritization of chronic disease management. These investments have strengthened national capacity to diagnose and manage diabetes complications, including severe hypoglycemia where glucagon plays a critical rescue role.
   
• The diabetes burden in Saudi Arabia is among the highest globally, creating substantial demand for glucagon. In 2024, the country had 5,344,600 adults living with diabetes, representing a 23.1% prevalence within an adult population of 24,983,100.
   
• This extremely high prevalence, more than double the global average reflects widespread insulin use, which increases the risk of serious hypoglycemic events and necessitates reliable access to emergency glucagon.
   
• Saudi Arabia’s growing elderly population further elevates demand for glucagon. Aging individuals experience higher rates of hypoglycemia unawareness, fluctuating insulin needs, and reliance on caregivers making portable, easy‑to‑use glucagon formulations increasingly important in both home and institutional settings.
   
• With one of the highest diabetes prevalence rates in the world, expanding healthcare capacity, and strong governmental investment in chronic‑disease management, Saudi Arabia is expected to remain a key growth market for glucagon across the Middle East throughout the forecast period.
   

Glucagon Market Share

The market is highly competitive, led by manufacturers advancing ready‑to‑use injectables and needle‑free intranasal rescue options. Leading companies are strengthening their positions through portfolio expansion (injectable + intranasal), device innovation (autoinjectors/prefilled syringes), and education partnerships that promote hypoglycemia readiness across hospitals, EMS, schools, and retail channels. Their strategies emphasize rapid‑acting formulations, simplified administration, and broad distribution to accelerate adoption and improve emergency outcomes in severe hypoglycemia.
 

Top 5 players in the market include Amphastar, Xeris Biopharma, Novo Nordisk, Fresenius Kabi, and Lupin. These players collectively accounted for around 42% share of the market in 2025 and have anchored their position in the global market through diversified delivery platforms and strong channel access. Close collaboration with hospitals, emergency services, diabetes associations, and regulators remains central to their playbooks, ensuring device usability in high‑stress scenarios, alignment with guideline‑driven preparedness, and timely approvals for next‑gen products.
 

Glucagon Market Companies

Some of the eminent market participants operating in the glucagon industry include:
 

• Amphastar Pharmaceuticals
• Avalon Pharma
• Eli Lilly and Company
• Fresenius Kabi
• Hanmi Pharmaceutical
• Lupin Limited
• Novo Nordisk A/S
• Taj Pharmaceuticals
• Xeris Biopharma Holdings
• Zealand Pharma
   

• Amphastar Pharmaceuticals
   

Amphastar is a leading innovator in the glucagon market, offering a diversified portfolio that strengthens its position in emergency hypoglycemia management. The company manufactures AP‑rated Glucagon for Injection; a bioequivalent rescue therapy used for rapid reversal of severe hypoglycemia and diagnostic GI procedures. By combining injectable and intranasal platforms, Amphastar supports broad clinical adoption across hospitals, pharmacies, EMS systems, and home‑care settings.
 

• Novo Nordisk
   

Novo Nordisk is a major global player in emergency glucagon therapy through its marketing and commercialization of Zegalogue (dasiglucagon), a next‑generation, ready‑to‑use analog designed for rapid treatment of severe hypoglycemia. The company’s competitive strength lies in its robust diabetes ecosystem, regulatory momentum, and global commercialization capabilities. Zegalogue has secured strong regulatory support, including FDA approval and a positive CHMP opinion in Europe, enabling expansion across key international markets.
 

• Lupin Limited
   

Lupin is an emerging competitor in the glucagon market, strengthening its position through the launch of Glucagon for Injection USP, 1 mg/vial, packaged as a complete emergency kit for managing severe hypoglycemia. The product is bioequivalent to Eli Lilly’s legacy glucagon injection, offering a clinically trusted alternative for U.S. healthcare providers. Lupin’s glucagon is indicated for both severe hypoglycemia rescue and diagnostic GI applications, enhancing its utility across acute‑care and imaging settings.
 

Glucagon Industry News:

• In August 2025, Lupin Limited announced the launch of its Glucagon for Injection USP, 1 mg/vial, in the United States, packaged as a complete emergency kit for severe hypoglycemia. The product is bioequivalent to Eli Lilly’s Glucagon for Injection (1 mg/vial) and is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes, as well as for use as a diagnostic aid during radiologic examinations to temporarily inhibit gastrointestinal motility, the launch reinforces Lupin’s expansion into critical diabetes‑care therapies and strengthens its U.S. injectables portfolio.
   
• In February 2020, Fresenius Kabi launched its Glucagon Emergency Kit in the U.S., containing Glucagon for Injection 1 mg and a prefilled glass syringe with 1 mL of Sterile Water for Injection. This FDA-approved kit provided a cost-effective solution for treating severe hypoglycemic episodes in people with diabetes, enhancing the company's market presence and meeting critical medical needs.
   

The glucagon market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Billion from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Injectable
• Inhalation

Market, By Application

• Hypoglycemia
• Diagnostic aid
• Gastrointestinal disorders
• Cardiogenic shock
• Other applications

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies   
   

The above information is provided for the following regions and countries:

• North America

• U.S.
• Canada

• Europe

• Germany
• UK
• France
• Spain
• Italy
• Russia
• Netherlands

• Asia Pacific

• China
• Japan
• India
• Australia
• South Korea

• Latin America

• Brazil
• Mexico
• Argentina

• Middle East and Africa

• South Africa
• Saudi Arabia
• UAE